Long-term Clinical Outcomes of Aspirin Desensitization With Continuous Daily Aspirin Therapy in Aspirin-exacerbated Respiratory Disease

Abstract

Background

Aspirin-exacerbated respiratory disease (AERD), also known as Samter’s triad or aspirin (ASA)-intolerant asthma, affects 7% of asthmatics and has a higher prevalence in those with chronic rhinosinusitis and concomitant nasal polyposis. ASA desensitization with daily ASA therapy is a uniquely beneficial treatment for this disease entity and has been shown to have a significant impact on symptom scores, polyp disease, and need for systemic corticosteroids. However, no long-term studies have demonstrated whether or not ASA therapy remains safe and beneficial for these patients beyond 5–10 years.

Objective

This study was designed to determine the clinical course of AERD patients desensitized between 1995 and 2010.

Methods

A 20-question survey was distributed to patients who successfully completed ASA desensitization between January 1995 and April 2010. The questions were designed to assess ASA safety and longitudinal effects of ASA therapy in AERD.

Results

Of the 285 patients contacted, 92 (32%) completed the questionnaire. Average length of follow-up was 15 years. Of survey responders, 35 patients had discontinued ASA therapy. Although adverse reactions occurred, many also discontinued due to lack of efficacy or need for surgery. For those remaining on ASA (62%), significant improvement in sense of smell, asthma, sinus, and allergic rhinitis scores were noted (P ≤ .001). The majority of ASA patients (68%) had a positive response to treatment and did not require further sinus surgery. However, ASA therapy did not delay the time to next sinus/polyp surgery (P = .27) or reduce total number of sinus surgeries (P = .56) compared to those who stopped treatment. Nearly 85% of AERD patients on ASA therapy found it to be helpful in improving airway disease and quality of life.

Conclusion

Aspirin desensitization followed by daily maintenance ASA therapy appears to be safe and effective even after 10+ years of continuous use.

Keywords

aspirin-exacerbated respiratory disease aspirin-intolerant asthma nasal polyps chronic rhinosinusitis Samter’s triad aspirin desensitization safety NSAID intolerance aspirin side effects questionnaire survey

Get full access to this article

View all access options for this article.

References

Samter

Beers

Jr.

Intolerance to aspirin: clinical studies and consideration of its pathogenesis.

Ann Intern Med. 1968; 68:975–983.

Stevenson

Simon

Mathison

DA.

Aspirin-sensitive asthma: tolerance to aspirin after positive oral aspirin challenges.

J Allergy Clin Immunol. 1980; 66:82–88.

Simon

State of the art: medical treatment of aspirin exacerbated respiratory disease (AERD).

Am J Rhinol Allergy. 2015; 29(1):41–43.

Stevenson

Pleskow

Simon

et al . Aspirin sensitive rhinosinusitis: a double-blind crossover study of treatment with aspirin. J Allergy Clin Immunol. 1984; 73:500–507.

Sweet

Stevenson

Simon

Mathison

DA.

Long term effects of aspirin desensitization treatment for aspirin sensitive rhinosinusitis asthma.

J Allergy Clin Immunol. 1900; 86:59–65.

Stevenson

Hankammer

Mathison

Christiansen

Simon

RA.

Long term ASA desensitization-treatment of aspirin sensitive asthmatic patients: clinical outcome studies. J Allergy Clin Immunol. 1996; 98:751–758.

McMains

Kountakis

SE.

Medical and surgical considerations in patients with Sampter’s triad.

Am J Rhinol. 2006; 20:573–576.

Havel

Ertl

Braunschweig

et al . Sinonasal outcome under aspirin desensitization following functional endoscopic sinus surgery in patients with aspirin triad. Eur Arch Otorhinolaryngol. 2012; 270(2):571–578.

Berges-Gimeno

Simon

Stevenson

DD.

Early effects of aspirin desensitization treatment in asthmatic patients with aspirin-exacerbated respiratory disease.

Ann Allergy Asthma Immunol. 2003; 90:338–341.

10.

Baruch

Holtom

BC.

Survey response rate levels and trends in organizational research.

Hum Relat. 2008; 61:1139–1160.

11.

Cardet

White

Barrett

et al . Alcohol-induced respiratory symptoms are common in patients with aspirin exacerbated respiratory disease. J Allergy Clin Immunol Pract. 2014; 2(2):208–213.

12.

Berges-Gimeno

Simon

Stevenson

DD.

Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease.

J Allergy Clin Immunol. 2003; 111(1):180–186.

13.

Pratt

Thompson

Elkin

Næsdal

Sörstadius

The impact of upper gastrointestinal symptoms on nonadherence to, and discontinuation of, low-dose acetylsalicylic acid in patients with cardiovascular risk. J Cardiovasc Drugs. 2010; 10(5):281–288.

14.

Makowska

Olszewska-Ziąber

Bieńkiewicz

et al . Clinical benefits of aspirin desensitization in patients with nonsteroidal anti-inflammatory drug exacerbated respiratory disease are not related to urinary eicosanoid release and are accompanied with decreased urine creatinine. Allergy Asthma Proc. 2016; 37(3):216–224.

15.

Cahill

Boyce

JA.

Aspirin-exacerbated respiratory disease: mediators and mechanisms of a clinical disease.

J Allergy Clin Immunol. 2017; 139(3):764–766.

16.

Kennedy

Stoner

Borish

Aspirin-exacerbated respiratory disease: prevalence, diagnosis, treatment, and considerations for the future.

Am J Rhinol Allergy. 2016; 30(6):407–413.